Gilead dan­gles $105M in quick cash to sign Schol­ar Rock to a dis­cov­ery deal for its grow­ing NASH pipeline

At last count Gilead $GILD had 3 clin­i­cal stage pro­grams for NASH in the pipeline, topped by their Phase III work on selon­sert­ib.

But that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.